ArticleFrontiers in immunology2025
Effect of bispecific recombinant oncolytic adenovirus carrying apoptin on apoptosis of MCF-7 cells.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, breast cancer cell line MCF-7 was infected with recombinant oncolytic adenovirus Ad-VT expressing apopsin protein, and its anti-tumour pathway was detected to determine its possible anti-tumour signalling pathway. Method: In this study, the inhibitory effect of recombinant oncolytic adenovirus Ad-VT on breast cancer cells was investigated through cell activity experiment and establishment of tumour bearing model in mice. Subsequently, in order to determine the apoptosis-inducing effect of recombinant oncolytic adenovirus on breast cancer cells, the effects of three recombinant oncolytic adenovirus on the apoptosis-inducing level of breast cancer cells were further analysed by Annexin V-FITC/PI detection, Hoechst staining, JC-1 staining and transmission electron microscopy. Then the differentially expressed proteins associated with apoptosis and possible signalling pathways were identified by proteomics and WB experiments. Results: Conclusion: Ad-VT can significantly increase the apoptosis level of breast cancer cells, which may be induced by the mTOR/S6K signalling pathway. The results of this study provide a theoretical basis for the development of anti-tumour drugs based on Ad-VT in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.